Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Eli Lilly
Eli Lilly
Top 10 pharma R&D budgets in 2022
Top 10 pharma R&D budgets in 2022
Fierce Biotech
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
Flag link:
Eli Lilly to increase investment to $1B into new Irish manufacturing facility — report
Eli Lilly to increase investment to $1B into new Irish manufacturing facility — report
Endpoints
Eli Lilly
Ireland
drug manufacturing
Flag link:
Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries
Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries
Fierce Pharma
Novo Nordisk
Rybelsus
diabetes
clinical trials
Eli Lilly
Flag link:
Will Eli Lilly Be a Trillion-Dollar Stock by 2030?
Will Eli Lilly Be a Trillion-Dollar Stock by 2030?
Motley Fool
Eli Lilly
Mounjaro
Flag link:
Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
PM Live
Roche
Eli Lilly
Alzheimer's disease
diagnostics
Flag link:
Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow
Flare fires up with $123M series B to target transcription factors with 3 Big Pharmas in tow
Fierce Biotech
Flare Therapeutics
funding
Pfizer
Eli Lilly
Novartis
transcription factors
Flag link:
AACR 2023 – Moderna's immunotherapeutic splash
AACR 2023 – Moderna's immunotherapeutic splash
EP Vantage
AACR
Moderna Therapeutics
Allogene
AstraZeneca
Merck
Roche
Novartis
Eli Lilly
Innovent
Springworks
Biogene
Relay Therapeutics
Vivace Therapeutics
Flag link:
Eli Lilly signs CSO Daniel Skovronsky to $5M non-compete clause
Eli Lilly signs CSO Daniel Skovronsky to $5M non-compete clause
Medical Marketing and Media
Eli Lilly
executives
Daniel Skovronsky
CSO
Flag link:
Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Endpoints
Sanofi
Lantus
insulin
diabetes
drug pricing
Eli Lilly
Novo Nordisk
Flag link:
SEC says Eli Lilly can't avoid requests for more info on diversity efforts, abortion stance
SEC says Eli Lilly can't avoid requests for more info on diversity efforts, abortion stance
Endpoints
Eli Lilly
SEC
abortion
diversity
DEI
Indiana
Flag link:
Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly
Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly
BioSpace
insulin
diabetes
drug pricing
Eli Lilly
Novo Nordisk
Flag link:
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli Lilly
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli Lilly
Forbes
Novo Nordisk
drug pricing
insulin
diabetes
Eli Lilly
Flag link:
Lilly’s Alzheimer’s struggles continue as preclinical asset fails phase III
Lilly’s Alzheimer’s struggles continue as preclinical asset fails phase III
BioSpace
Eli Lilly
Alzheimer's disease
solanezumab
clinical trials
Flag link:
Eli Lilly kicks off consumer campaign for diabetes drug Mounjaro
Eli Lilly kicks off consumer campaign for diabetes drug Mounjaro
Medical Marketing and Media
Eli Lilly
Mounjaro
diabetes
DTC ads
Flag link:
Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med
Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med
Fierce Biotech
Volastra Therapeutics
Eli Lilly
funding
sovilnesib
Amgen
cancer
Flag link:
FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands
FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands
Fierce Pharma
Eli Lilly
Verzenio
breast cancer
Flag link:
Sanders urges Sanofi, Novo Nordisk to be like Eli Lilly in reducing insulin prices
Sanders urges Sanofi, Novo Nordisk to be like Eli Lilly in reducing insulin prices
Fierce Pharma
Eli Lilly
Novo Nordisk
Sanofi
insulin
Bernie Sanders
drug pricing
Flag link:
Eli Lilly licenses non opioid pain med for $40M upfront
Eli Lilly licenses non opioid pain med for $40M upfront
Seeking Alpha
Eli Lilly
Confo Therapeutics
non-opioid pain treatments
CFTX-1554
Flag link:
Lilly to cut insulin prices by 70%, cap prices at $35 per month for people with private insurance
Lilly to cut insulin prices by 70%, cap prices at $35 per month for people with private insurance
CNBC
Eli Lilly
drug pricing
diabetes
insulin
Humalog
Humalin
Flag link:
Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report
Big-sellers from Merck, Novo and Lilly likely to face Medicare price negotiations: report
Fierce Pharma
Medicare
drug pricing
Merck
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
JNJ
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »